Feinstein Institutes' Thrombosis Expert Named Fulbright Scholar

Event summary

  • Alex C. Spyropoulos, MD, Professor at Feinstein Institutes, awarded Fulbright U.S. Scholar for 2026-2027.
  • Spyropoulos recognized for research in thrombosis, anticoagulation, and global multicenter clinical trials.
  • Fulbright Program supports international research collaboration in over 160 countries.
  • Spyropoulos co-authored NEJM editorial on intermediate-risk pulmonary embolism treatment.
  • Feinstein Institutes houses 50+ research labs and 5,000 researchers across six medical research institutes.

The big picture

The Fulbright recognition underscores the strategic importance of international collaboration in medical research, particularly in specialized fields like thrombosis. Feinstein Institutes' focus on bioelectronic medicine and large-scale clinical trials positions it as a key player in advancing global health initiatives. The award highlights the growing intersection of academic research and real-world clinical applications, driving innovation in patient care.

What we're watching

Research Impact
How Spyropoulos' Fulbright-funded international collaborations will accelerate thrombosis research and treatment protocols.
Industry Collaboration
Whether Feinstein Institutes can leverage this recognition to attract more global partnerships in medical research.
Regulatory Influence
The pace at which Spyropoulos' findings on anticoagulation therapies may shape clinical guidelines and regulatory approvals.